ClinicalTrials.gg
CompletedNCT04512872Updated Sep 1, 2021

A Phase I Study to Evaluate the Safety and Pharmacokinetics of CT-P41 and EU-approved Prolia in Healthy Male Subjects

A Phase 1 interventional study of CT-P41 and EU-approved Prolia in Healthy Male Subjects, sponsored by Celltrion. Completed at 1 site in Australia. Open to male participants aged 28 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-09-01.

Sponsored by Celltrion · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
28 Years to 55 Years
Sex
Male
01

Study summary

This study is a Pilot Phase 1, Double-Blind, Randomized, Two-arm, Parallel group, Single-dose Study to Evaluate the Safety and Pharmacokinetics of CT-P41 and EU-approved Prolia in Healthy Male Subjects

Read the detailed description

This study is a pilot phase 1, randomized, double-blind, two-arm, parallel group, single-dose study, which is designed to evaluate the safety, immunogenicity, PK and PD of CT-P41 and EU-approved Prolia in healthy male subjects. Approximately 30 male subjects will be enrolled and randomly assigned to one of the two treatment arms in a 1:1 ratio. In each treatment group, all subjects will receive a single 60 mg dose of either CT P41 or EU-approved Prolia by subcutaneous injection via a PFS on Day 1, followed by 134 days of safety, immunogenicity, PK, and PD measurements.

02

Conditions studied

  • Healthy Male Subjects
03

In context

Lead sponsor

Celltrion is the lead sponsor of 77 studies on the registry; 2 are open to participants now.

Of its 19 completed or terminated interventional studies of FDA-regulated products, 14 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
28 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male subjects, between the ages of 28 and 55 years.
  • Subject with a between 18.5 and 29.9 kg/m2.
  • Subject with albumin-adjusted total serum calcium ≥8.5 mg/dL (≥2.125 mol/L) and serum 25-OH vitamin D ≥20 ng/ml.
  • Male subject and their female partner of must agree to use a highly effective method of throughout the study and for 5 months after the study drug administration.

Exclusion criteria

Exclusion Criteria:

  • Subject with a to any component of denosumab.
  • Subject has a history of and/or current known risk factors for hypocalcemia and osteonecrosis of jaw, and any illness at investigator's discretion.
  • Subject has a history of and/or concurrent use of medications such as an drug, monoclonal antibody, fusion protein, and biologics.
  • Subject has a history of and/or concurrent use of any therapy that might significantly affect bone metabolism.
  • Subject is vulnerable.
  • Subject is not likely to complete the study for whatever reason in the opinion of the Investigator.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    CT-P41

    60 mg/mL single dose administration, Solution for injection in PFS

    Biological: CT-P41

  • Active comparator
    EU-approved Prolia

    60 mg/mL single dose administration, Solution for injection in PFS

    Biological: EU-approved Prolia

Interventions

  • BiologicalCT-P41

    60 mg/mL single dose, Solution for injection in PFS

  • BiologicalEU-approved Prolia

    60 mg/mL single dose, Solution for injection in PFS

06

What researchers measure

Primary outcomes

  1. Evaluate safety

    safety in terms of treatment-emergent adverse events (TEAEs) of CT-P41 compared to that of EU-approved Prolia

    Time frame: through study completion, up to day 134

07

Study locations

1 site
  • Q-Pharm Pty Ltd
    Herston, Queensland 4006, Australia
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2020 to primary completion in May 2021, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 11, 2020
First posted
Aug 14, 2020
StartActual
Oct 20, 2020
Primary completionActual
May 4, 2021
CompletionActual
May 4, 2021
Last update
Sep 1, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 1, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04512872
Lead sponsor
Celltrion
Responsible party
Sponsor
First posted
Aug 14, 2020
Start date
Oct 20, 2020
Primary completion
May 4, 2021
Completion
May 4, 2021
Last update
Sep 1, 2021

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Denosumab

Start the discussion